IMARC Group\'s report titled “Influenza Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028“, The global influenza diagnostics market size reached US$ 893.4 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 1,461.7 Million by 2028, exhibiting a growth rate (CAGR) of 6.55% during 2023-2028.

Influenza, commonly known as the flu, is a highly contagious infectious disease caused by a virus. It primarily affects the nose, throat, and lungs, leading to symptoms such as severe aches and fever. Diagnosis of influenza involves various methods such as immunofluorescence assays, serology, viral culture, rapid antigen testing, rapid influenza diagnostic tests (RIDTs), reverse transcription polymerase chain reaction (RT-PCR), and rapid molecular assays. These procedures utilize immunoassay tests to detect the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens and provide qualitative results, indicating whether the test is positive or negative. Consequently, influenza diagnostic solutions are widely utilized in hospitals and diagnostic laboratories worldwide.

For an in-depth analysis, you can refer sample copy of the report: https://www.imarcgroup.com/influenza-diagnostics-market/requestsample

Influenza Diagnostics Market Trends and Drivers:

The market for influenza diagnostics is primarily driven by several factors. One of the main drivers is the increasing prevalence of chronic diseases that elevate the risk of influenza, such as cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, and bronchiectasis. Additionally, the rapid influenza diagnostic test (RIDT) is gaining popularity due to its convenience and ability to provide results in a shorter time frame, which is accelerating its adoption worldwide. The introduction of technologically advanced influenza diagnostic tests that integrate influenza A and B with rapid antigen tests for coronavirus disease (COVID-19) is also a significant growth-inducing factor. Moreover, the integration of artificial intelligence (AI) in influenza diagnostics to reduce sample processing time and ensure accurate results is driving market growth. Furthermore, the growing geriatric population, which is more susceptible to respiratory tract infections, and the implementation of government policies to mitigate the risk of influenza are propelling the market forward.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Product:

• Test Kit and Reagents
• Instruments
• Others

Breakup by Test Type:

• Molecular Diagnostic Tests
  • Polymerase Chain Reaction
  • Isothermal Nucleic Acid Amplification Tests
  • Other Molecular Tests
• Traditional Diagnostic Tests
  • Rapid Influenza Diagnostic Tests
  • Viral Culture Tests
  • Direct Fluorescent Antibody Test
  • Serological Tests 

Breakup by Type of Flu:

• Type A Flu
• Type B Flu
• Type C Flu

Breakup by End User:

• Hospitals
• Diagnostic Laboratories
• Others

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Competitive Landscape with Key Player:

• Abbott Laboratories
• Becton Dickinson and Company
• Coris Bioconcept
• Danaher Corporation
• DiaSorin S.p.A.
• Hoffmann-La Roche Ltd (Roche Holding AG)
• Hologic Inc.
• Meridian Bioscience Inc.
• Qiagen N.V, Quidel Corporation
• Sekisui Diagnostics LLC (Sekisui Medical Co. Ltd.)
• and Siemens Healthineers AG (Siemens AG)

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

IMARC Group

Email: sales@imarcgroup.com

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA

Follow us on Twitter: @imarcglobal